2024
Changes in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act
Demkowicz P, Buck M, Nie J, Marks V, Wheeler S, Dinan M, Gross C, Leapman M. Changes in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act. Urology 2024, 192: 19-27. PMID: 38901803, DOI: 10.1016/j.urology.2024.06.003.Peer-Reviewed Original ResearchFacility-level changesAffordable Care ActNon-expansion statesUrological cancer patientsProportion of patientsExpansion statesBaseline proportion of patientsUrologic cancer careHigh-income zip codesCancer patientsFactors associated with changesPre-post designCancer care centerPost-ACA periodMedicaid expansion statesMultivariate logistic regressionMedicaid-insured patientsCancer careUrological cancersZip codesCare ActMedicaid patientsMedicaidLogistic regressionCare centerACO leakage among gynecologic cancer patients: Incidence, predictors, and impact on annual Medicare expenditure
Osazuwa-Peters O, Greiner M, Kaufman B, Zambrano Guevara L, Dinan M, Havrilesky L, Moss H. ACO leakage among gynecologic cancer patients: Incidence, predictors, and impact on annual Medicare expenditure. Gynecologic Oncology 2024, 187: 184-191. PMID: 38788516, DOI: 10.1016/j.ygyno.2024.05.020.Peer-Reviewed Original ResearchAccountable care organizationsGynecologic cancer patientsACO sizeYear of cancer diagnosisReceipt of healthcareLog-binomial regression modelsCancer patientsNon-ACO providersPatients seeking careAdjusted risk ratiosHealth care costsAnnual Medicare expendituresMedian household incomeAssociated with useCare organizationsOutpatient careMedicare expendituresCare costsHealthcare costsMedicare spendingCancer diagnosisOutpatient settingHousehold incomeRisk ratioMultivariable adjusted risk ratios
2023
Characteristics, healthcare utilization, and outcomes of patients with HER2-low breast cancer
Check D, Jackson B, Reeder-Hayes K, Dinan M, Faherty E, Kwong J, Mehta S, Spees L, Wheeler S, Wilson L, Lam C. Characteristics, healthcare utilization, and outcomes of patients with HER2-low breast cancer. Breast Cancer Research And Treatment 2023, 203: 329-338. PMID: 37875669, DOI: 10.1007/s10549-023-07142-4.Peer-Reviewed Original ResearchConceptsHER2-low breast cancerBreast cancerHealthcare utilizationOutcomes of patientsRetrospective cohort studyStage IV diseaseStage IV patientsMetastatic breast cancerNew treatment guidelinesRate of hospitalizationBreast cancer patientsClinical characteristicsCohort studyHazard ratioIV patientsOverall cohortPositive diseaseTreatment guidelinesIHC 0Utilization outcomesTreatment optionsCancer patientsSurvival differencesPatientsStage IV
2019
Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer
Rotter J, Wilson L, Greiner MA, Pollack CE, Dinan M. Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer. Breast Cancer Research And Treatment 2019, 176: 445-451. PMID: 31028607, PMCID: PMC6556129, DOI: 10.1007/s10549-019-05248-2.Peer-Reviewed Original ResearchConceptsPatient-level analysisOncotype DXBreast cancerMedical oncologistsEarly-stage breast cancerGenomic testingPhysician networksODX testingMore patientsRetrospective studySEER-MedicareStudy criteriaSuboptimal treatmentCancer patientsMedian numberModifiable driversModifiable meansPatientsOncologistsLogistic mixed modelsEarly adoption periodWomenCancerPhysiciansGenomic assays
2018
Nationwide utilization and costs of targeted anti-cancer drugs for elderly patients with solid tumors in the United States, 2004-2015.
Wilson L, Greiner M, Altomare I, Rotter J, Dinan M. Nationwide utilization and costs of targeted anti-cancer drugs for elderly patients with solid tumors in the United States, 2004-2015. Journal Of Clinical Oncology 2018, 36: 23-23. DOI: 10.1200/jco.2018.36.30_suppl.23.Peer-Reviewed Original ResearchTargeted anti-cancer drugsCancer spendingCancer patientsD patientsBC patientsAnti-cancer drugsColorectal cancer populationPatients age 65Breast cancer patientsLung cancer patientsMedicare spendingElderly lungsElderly patientsPatient ageCC patientsLC patientsMedicare 5Colorectal cancerInvasive lungPatient populationCancer populationMedicare patientsNationwide utilizationRetrospective analysisMean cost
2016
ONCOLOGISTS’ BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY
Roberts MC, Bryson A, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes K, Wheeler SB. ONCOLOGISTS’ BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY. International Journal Of Technology Assessment In Health Care 2016, 32: 355-361. PMID: 27958190, PMCID: PMC6526532, DOI: 10.1017/s026646231600060x.Peer-Reviewed Original ResearchConceptsAdjuvant chemotherapy decisionsBreast cancer patientsOncotype DXTreatment decisionsCancer patientsChemotherapy decisionsHormone receptor-positive breast cancer patientsClinical practiceReceptor-positive breast cancer patientsPositive breast cancer patientsOncotype DX useUnited States guidelinesProfiling testsEligible womenSurgical oncologistsCancer careClinical guidelinesModifiable barriersOncologistsMulti-level factorsPatientsThematic saturationPhone interviewsIntermediate scoresQualitative study
2015
Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing
Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Troester MA, Carey LA, Wheeler SB. Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing. Breast Cancer Research And Treatment 2015, 153: 191-200. PMID: 26216535, PMCID: PMC4562432, DOI: 10.1007/s10549-015-3518-9.Peer-Reviewed Original ResearchConceptsAdjuvant chemotherapy initiationChemotherapy initiationRisk scoreODX testingCarolina Breast Cancer StudyIntermediate-risk groupRacial variationBreast cancer patientsPopulation-based studyHigh-risk groupLarger tumor sizeLow-risk groupOncotype DX testingRacial differencesNorth Carolina womenBreast Cancer StudyAdjuvant chemotherapyTumor sizeCancer patientsRelative riskRisk groupsBreast cancerPoisson regressionYounger agePhase IIIImpact of Extent of Surgery on Survival for Papillary Thyroid Cancer Patients Younger Than 45 Years
Adam M, Pura J, Goffredo P, Dinan MA, Hyslop T, Reed SD, Scheri RP, Roman SA, Sosa JA. Impact of Extent of Surgery on Survival for Papillary Thyroid Cancer Patients Younger Than 45 Years. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 115-121. PMID: 25337927, PMCID: PMC5399499, DOI: 10.1210/jc.2014-3039.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancer patientsTotal thyroidectomyOverall survivalThyroid cancer patientsImpact of extentYears of ageCancer patientsNational Cancer Data BaseUnadjusted overall survivalLymph node diseaseExtent of resectionEnd Results (SEER) datasetAdult patientsClinical characteristicsExcellent prognosisNode diseasePathologic factorsImproved survivalThyroid lobectomyTumor sizeCurrent guidelinesMultivariable modelingLobectomyMAIN OUTCOMEThyroidectomy
2014
Association between CT utilization and radiation therapy at the end of life (EOL) in elderly breast and prostate cancer patients.
Dinan M, Curtis L, Setoguchi S, Cheung W. Association between CT utilization and radiation therapy at the end of life (EOL) in elderly breast and prostate cancer patients. Journal Of Clinical Oncology 2014, 32: 6529-6529. DOI: 10.1200/jco.2014.32.15_suppl.6529.Peer-Reviewed Original Research